Clinical trials: COVID-19 Vaccination
Myocardial Injury, Myocarditis
Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)
The study will focus on cardiac blood and imaging biomarkers to facilitate early recognition of patients at risk for myocardial injury after COVID-19 vaccination.
- Conditions
- Myocardial Injury, Myocarditis, COVID-19 Vaccination, SARS-CoV-2
- Trial name
- MYOVAX (NCT04967807)
- Testing
- Cardiac PET/MRI, Blood Biomarkers
- Where
- Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Acute Coronary Syndrome, Chronic Heart Failure
Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure
Study Description: Background: Well-known fact that the number of cardiovascular diseases is on the rise during influenza epidemic.
- Trial name
- IV-ACS&CHF (NCT05232292)
- Testing
- Ultrix Quadri
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Samara Regional Cardiology Dispensary
Vaccination Refusal
Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)
Working with governments in Bihar, India, we will evaluate a number of mechanisms to increase vaccine uptake. These include household vaccination visits instead of community vaccination clinic.monetary and non-monetary…
- Trial name
- NCT05225064
- Testing
- Incentives to be vaccinated, Mask, Encouragement to wear a mask
- Where
- India
- Volunteers
- 114,512 people, healthy volunteers welcome
- Sponsor
- Yale University
SARS-CoV2 Infection, SARS-CoV2 Antibodies
Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study
Great expectations to control the pandemic are placed in vaccines against COVID-19. Currently, the four COVID-19 vaccines approved in the European Union.
- Trial name
- DANTE-SIRIO 7 (NCT05109585)
- Testing
- assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule, assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
- Where
- Poland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Collegium Medicum w Bydgoszczy
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
This is a phase 1, open-label, randomized clinical trial in males and non-pregnant females, 18 years of age and older, who are in good health, have no known history of COVID-19 or SARS-CoV-2 infection, and meet all other…
- Trial name
- NCT04785144
- Testing
- mRNA-1273, mRNA-1273.351
- Where
- 4 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Discussing COVID-19 Vaccines in Private Facebook Groups
As the COVID-19 pandemic persists, a sizable proportion of the U.S. population remains unvaccinated and at high risk of death and serious illness from COVID-19.
- Trial name
- NCT05422898
- Testing
- Gist messages on COVID-19 vaccination, COVID-19 vaccine information
- Where
- United States
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- George Washington University
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- COVID-19 (NCT05239832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Old Age; Debility, Vaccine Hesitancy
COVID-19 Vaccination Willingness in Older Adults Based on Self-determination Theory
Introduction: The COVID-19 vaccine is an effective measure for preventing and controlling COVID-19 epidemics, and the World Health Organization lists older adults as a high-priority group for COVID-19 vaccination.
- Conditions
- Old Age; Debility, Vaccine Hesitancy, Vaccine Refusal
- Trial name
- CVWIOABOSDT (NCT06575114)
- Testing
- Self-determination theory-based health education measures
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Jing-Shan Deng
Infection, Viral, Agent as Cause of Disease Classified Elsewhere
Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers
Healthcare Workers (HCW) are at high risk for COVID-19. In addition to the risk of serious forms among HCW, significant absenteeism due to illness would have dramatic consequences in our ability to fight COVID-19.
- Trial name
- COVID-BCG (NCT04384549)
- Testing
- BCG GROUP
- Where
- France
- Volunteers
- 1,120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV-2 Infection, Active Immunization
Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff
To investigate short- (3 and 8 weeks) and long-term (6, 9, 12, and 18 months) immune protection or response at the humoral and cellular levels before and after SARS-CoV-2 infection or vaccination in patients with moderately…
- Conditions
- SARS-CoV-2 Infection, Active Immunization, Immune Response, Immunosuppression
- Trial name
- DIA-Vacc (NCT04799808)
- Where
- Germany
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
COVID-19
Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)
This is a randomised controlled clinical trial to determine the reactogenicity and immunogenicity of booster doses of SARS-CoV-2 vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) in adults who have previously received either…
- Trial name
- NCT05387317
- Testing
- Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose
- Where
- 3 sites in Indonesia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Wellness, Burnout, Caregiver
Evaluating the Impact of Resource Navigators to Support LTC and RH Staff During and Beyond COVID-19
The goal of this clinical trial is to test how well resource navigators help long-term care and retirement home staff access the various health and wellness resources available to them and the effects that this has on their…
- Conditions
- Wellness, Burnout, Caregiver, Burnout, Professional, COVID-19
- Trial name
- NCT05677997
- Testing
- Intervention
- Where
- Canada
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
COVID-19, Influenza
Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza…
- Trial name
- DAN-COMBO (NCT07790523)
- Testing
- mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)
- Where
- 3 sites in Denmark, Spain
- Volunteers
- 410,000 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Spinal Cord Injuries, Traumatic Spinal Cord Injury
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2).
- Conditions
- Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine
- Trial name
- SCIVAX (NCT05869968)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Vaccination, Covid19
The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions
Uptake of vaccination against COVID-19 is key to controlling the pandemic. However, a significant proportion of people report that they do not intend to have a vaccine, often because of concerns they have about its side effects…
- Trial name
- NCT04813770
- Testing
- Theory-based messages, General messages
- Where
- United Kingdom
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
SARS-CoV-2
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM…
- Trial name
- NCT05181709
- Testing
- Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sean Liu
Covid-19 Vaccine, Vaccine Hesitancy
PROmotion of COvid-19 VA(X)Ccination in the Emergency Department - PROCOVAXED
The goal of this research is to increase COVID-19 vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients).
- Trial name
- PROCOVAXED (NCT05142332)
- Testing
- Covid-19 vaccine education materials
- Where
- 7 sites in United States
- Volunteers
- 541 people
- Sponsor
- University of California, San Francisco
COVID-19
COVID Booster in Pregnancy and Lactation
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.
- Trial name
- NCT05543993
- Testing
- Bivalent COVID-19 Booster
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Covid 19, BCG Vaccination
Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study
Covid-19 In Tunisia: AN Observational Cross-Sectional Registry Study
- Trial name
- CONNAITRE (NCT04384614)
- Testing
- Test PCR, TDR, Clinical Examination
- Where
- Tunisia
- Sponsor
- Direction des Soins de Santé de Base
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD